|
Treatment
Overview or Chemotherapy >
Common combinations
Last update: 06/23/2009
|
|
A
| B | C | D | E
| F | G | H | I
| J | K | L | M
| N | O | P | Q
| R | S | T | U
| V | W | X |
Y | Z |
APO
|
A
= Doxorubicin (Adriamycin®) Rubex® Antitumor Antibiotic
P = Prednisolone
O = Vincristine ((Oncovin®) Blocks Cell Duplication
and Methotrexate
(substituted for Doxorubincin when toxicity threshold is reached.) |
ATT
|
Alternating Triple Therapy. The protocol involves a sequence
of three regimens, CHOD-Bleo, ESHAP, and NOPP. The drugs in these
regimens include:
cyclophosphamide, doxorubicin, vincristine,
belomycin, VP-16, cisplatin, mitoxantrone, procarbazine, and corticosteriods (prednisone, methylprednione,
dexamethasone.) The only overlap with FND is the mitoxantrone and dexamethasone.
|
BEAM Mini
|
 TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
B
= Carmustine (BCNU®) DNA-Altering
E = Etoposide (VP-16,
VePesid®) DNA Repair Enzyme
Inhibitor
A = Cytarabine (Ara-C®, Cytosar®) Antimetabolites
M =
Melphalan (Alkeran®) DNA-Altering
Details on BEAM: spitfire.emmes.com
|
Bendamustine
/ Treanda
Bendamustine
(SDX-105)
cytotoxic
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
B
= Bendamustine (bifunctional agent with both alkylator and purine-like
activity)
R = Rituxan
- Monoclonal antibody against CD20
|
BEAC
BEAC
or BEAM?
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
B
= Carmustine (BCNU®) DNA-Altering
E = Etoposide (VP-16,
VePesid®) DNA Repair Enzyme
Inhibitor
A = Cytarabine (Ara-C®, Cytosar®) Antimetabolites
While BEAC and BEAM appears to have equal antitumour
efficacy in patients with NHL, BEAM seems to be more toxic to the
gastrointestinal tract. However, randomized studies are needed for more
definitive conclusions on the relative merits of various high-dose
regimens in patients with NHL. PMID:
12916867
|
CHOP
CHOP + R
For aggressive or
indolent lymphoma
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
C
= Cyclophosphamide
(Cytoxan®) DNA-Altering
H = Doxorubicin (Adriamycin®) or Rubex® or Hydroxydaunomycin Antitumor
Antibiotic
O = Vincristine
(Oncovin®) Blocks Cell Duplication
P =
Prednisone (Deltasone®) steroidal:
anti-inflammatory, Immunosuppressant
R = Rituxan
- Monoclonal antibody against CD20 (addition of Rituxan has become
standard)
|
CEOP-R
CHOP-like chemotherapy
|
C
= Cyclophosphamide (Cytoxan®) DNA-Altering
O = Vincristine (Oncovin®) Blocks Cell Duplication
E = Epirubicin
Epirubicin, anthracyline
drug nlm.nih.gov
P =
Prednisone (Deltasone®)
steroidal:
anti-inflammatory, Immunosuppressant
|
CODOX-M
|
C
= Cyclophosphamide (Cytoxan®) DNA-Altering
O = Vincristine (Oncovin®) Blocks Cell Duplication
D = Doxorubicin (Adriamycin®) Rubex® Antitumor Antibiotic
M = Methotrexate (Rheumatrex®) Antitumor Antibiotic |
COPBLAM
|
C
= Cyclophosphamide
(Cytoxan®) DNA-Altering
O = Vincristine (Oncovin®) Blocks Cell Duplication
P = Prednisone (Deltasone®) steroidal:
anti-inflammatory, Immunosuppressant
B = Bleomycin (Blenoxane®) Antitumor Antibiotic
A = Doxorubicin (Adriamycin®) Rubex® Antitumor Antibiotic
M = Procarbazine (Matulane®) DNA-Altering |
CP
|
C
= Chlorambucil
(Leukeran®) DNA-Altering
P = Prednisone (Deltasone®) steroidal:
anti-inflammatory, Immunosuppressant |
CVP
CVP + R
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
C
= Cyclophosphamide
(Cytoxan®) DNA-Altering
V = Vincristine (Oncovin®) Blocks Cell Duplication
P = Prednisone (Deltasone®) steroidal:
anti-inflammatory, Immunosuppressant
R = Rituxan
- Monoclonal antibody against CD20 (addition of Rituxan has become
standard)
|
CyMiR
|
Cyclophosphamide
Mitoxantrone
Rituxan |
DHAP
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
D
= Dexamethasone
(Decadron®) steroidal:
anti-inflammatory, Immunosuppressant
HA = Cytarabine (Ara-C, Cytosar®) Antimetabolites
P = Displatin (Platinol®) DNA-Altering
 |
Oxaliplatin Appears Effective (as cisplatin in DHAP & safer)
in Treatment Regimen for Recurrent NHL -
CancerConsultants.com
|
|
DICE
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
D
= Dexamethasone
(Decadron®) steroidal:
anti-inflammatory, Immunosuppressant
I = ifosfamide (ifek®) DNA-Altering
C = Cisplatin (Platinol®) DNA-Altering
E = Etoposide (VP-16, VePesid®) DNA Repair Enzyme Inhibitor
|
EPOCH
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
E
= Etoposide (VP-
16, VePesid®) DNA Repair Enzyme Inhibitor
P = Prednisone (Deltasone®) steroidal:
anti-inflammatory, Immunosuppressant
O = Vincristine (Oncovin®) Blocks Cell Duplication
C = Cyclophosphamide (Cytoxan®) DNA-Altering
H =Doxorubicin (Adriamycin®) Antitumor Antibiotic
|
ESHAP
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
E
= Etoposide
(VP-16, VePesid®) DNA Repair Enzyme Inhibitor
S = Methylprednisolone
(Medrol®) steroidal: anti-inflammatory,
Immunosuppressant
HA = Cytarabine
(Ara-C®, Cytosar®) Antimetabolites
P = Cisplatin (Platinol®) ) DNA-Altering
Alert: Severe hypomagnesaemia
(low magnesium) with tetany following ESHAP protocol - http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=64621
|
Fludarabine
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
Fludarabine
(Fludara ®) Antimetabolites
|
Fludarabine
+ Rituxan
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
Fludarabine
(Fludara ®) Antimetabolites
R = Rituxan
- Monoclonal antibody against CD20
|
FCR
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
F=
Fludarabine
(Fludara ®) Antimetabolites
C = Cyclophosphamide (Cytoxan®) DNA-Altering
R = Rituxan- Monoclonal antibody against CD20
|
FND
FND + R or R-FND
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
F=
Fludarabine
(Fludara ®) Antimetabolites
N = Mitoxantrone (Novantrone®) Antitumor Antibiotic
D= Dexamethasone
steroidal:
anti-inflammatory, Immunosuppressant
R = Rituxan- Monoclonal antibody against CD20
Also see:
|
FCM+R
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
F=
Fludarabine
(Fludara ®) Antimetabolites
C = Cyclophosphamide (Cytoxan®) DNA-Altering
Mitoxantrone ( mye-toe-ZAN-trone) DNA intercalation; DNA topoisomerase II inhibition
R = Rituxan- Monoclonal antibody against CD20
|
HDMTX
|
High
dose Methotrexate (Rheumatrex®) Antimetabolites
Details - ptmd.com |
hyperCVAD
or
R-hyperCVAD
... now with Rituxan
for MCL
Hyper CVAD Followed by SCT for MCL - PubMed
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
C = twice daily
Cyclophosphamide (Cytoxan®) DNA-Altering
V = Vincristine (Oncovin®) Blocks Cell Duplication
A = Doxorubicin (Adriamycin®) Rubex® Antitumor Antibiotic
D = Dexamethasone
steroidal:
anti-inflammatory, Immunosuppressant
The above is alternated
with high dose Methotrexate, and Ara-C
.
Ara-C®, Cytosar®) Antimetabolites
Methotrexate (Rheumatrex®) Antimetabolites
"The
hyperCVAD regimen actually involves two regimens. The hyperCVAD
combination is alternated with high doses of methotrexate and cytarabine
for four courses. Then high-dose cyclophosphamide and total-body
irradiation are followed by autologous stem cell transplantation." - MDACC
| About the hyperCVAD protocol- cancercare.on.ca
PDF
Treatment schedule, side effects, monitoring ...
|
|
Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD/High-dose
methotrexate and cytarabine (M-C) (±rituximab) improves results of
autologous stem cell transplant in first remission. - ASCO
2006
|
|
ICE
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
I
= Ifosfamide (Ifex®) DNA-Altering
C = Carboplatin
(Paraplatin®) DNA-Altering
E= Etoposide (VP-16,
VePesid®) DNA Repair Enzyme
Inhibitor
|
IMVP-16
|
I
= Ifosfamide
(Ifex®) DNA-Altering
M = Methotrexate
(Rheumatrex®) Antitumor Antibiotic
VP = Etoposide (VP-16, VePesid®) DNA Repair Enzyme
Inhibitor |
MACOP-B
|
M
= Methotrexate
(Rheumatrex®) Antimetabolites
A = Doxorubicin (Adriamycin®, Rubex®) Antitumor
Antibiotic
C = Cyclophosphamide (Cytoxan®) DNA-Altering
O = Vincristine (Oncovin®) Blocks Cell Duplication
P = Prednisone (Deltasone®) steroidal:
anti-inflammatory, Immunosuppressant
B = Bleomycin (Blenoxane®) Antitumor Antibiotic |
MOPP/ABV
Randomized comparison of ABVD and MOPP/ABV hybrid for the
treatment of advanced Hodgkin's disease: report of an intergroup
trial. J Clin Oncol. 2003 Feb 15;21(4):607-14.
PMID: 12586796 - PubMed
|
(MOPP)
M = Mechlorethamine,
V = Vincristine
P = Procarbazine
P = Prednisone
(ABVD)
A = Doxorubicin
B = Bleomycin
V = Vinblastine
D = Dacarbazine
|
M-BACOD
|
M
= Methotrexate
(Rheumatrex®) Antimetabolites: interfers with
normal growth
B = Bleomycin (Blenoxane®) Antitumor Antibiotic
A = Doxorubicin (Adriamycin®, Rubex®) Antitumor
Antibiotic
C = Cyclophosphamide (Cytoxan®) DNA-Altering
V = Vincristine (Oncovin®) Blocks Cell Duplication
D = Dexamethasone steroidal:
anti-inflammatory, Immunosuppressant |
O-DICE
|
|
SALVAGE: Phase II study of dexamethasone, ifosfamide, cisplatin
and etoposide delivered on an outpatient basis (O-DICE), as salvage
chemotherapy for patients with relapsed and refractory lymphoma Year:
2002 Abstract No: 1136
|
|
PEP-C
|
P
= Prednisone
(Deltasone®)
E = Etoposide (VP-16, VePesid®) DNA Repair Enzyme Inhibitor
P = Procarbazine (Matulane®)
C= Cyclophosphamide (Cytoxan®) DNA-Altering |
PMitCEBO
|
P = Prednisone (Deltasone®) steroidal:
anti-inflammatory, Immunosuppressant
Mit = Mitoxantrone ( mye-toe-ZAN-trone) DNA intercalation; DNA topoisomerase II inhibition
C = Cyclophosphamide (Cytoxan®) DNA-Altering
E = Etoposide (VP-16,
VePesid®) DNA Repair Enzyme
Inhibitor
B = Bleomycin (Blenoxane®) Antitumor Antibiotic
O = Vincristine (Oncovin®) Blocks Cell Duplication
|
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF
in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
Br J Cancer. 2006 Mar 27;94(6):806-13. PMID:
16508640
|
|
Pro-MACE-
CytaBOM
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
Prednisone
(Deltasone®)
Methotrexate (Rheumatrex®) Antimetabolites:
interfers with normal growth
Doxorubicin (Adriamycin®, Rubex®) Antitumor
Antibiotic
Cyclophosphamide (Cytoxan®) DNA-Altering
Etoposide (VP-16, VePesid®) DNA Repair Enzyme
Inhibitor
Cytarabine (Ara-C', Cytosar®) Antimetabolites:
interfers with normal growth
Bleomycin (Blenoxane®) Antitumor Antibiotic
Vincristine (Oncovin®) Blocks Cell Duplication
|
RICE
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
R
= Rituxan- Monoclonal antibody against CD20
I = Ifosfamide (Ifex®) DNA-Altering
C = Carboplatin
(Paraplatin®) DNA-Altering
E = Etoposide (VP-16,
VePesid®) DNA Repair Enzyme
Inhibitor
|
VBM
Efficacy of
vinblastine, bleomycin, methotrexate (VBM) chemotherapy with involved field radiotherapy in early stage
(I-IIA)
Hodgkin disease patients. Leuk Lymphoma. 2003 Nov;44(11):1919-23.
Review. PMID:
14738143 | Related
articles
|
TOPIC
SEARCH on outcomes: ASCO
| Medscape
| PubMed
| Web
on risks: ASCO
| Medscape
| PubMed
| Web
V = vinblastine (Oncovin®) Blocks Cell Duplication
B = bleomycin, (Blenoxane®) Antitumor Antibiotic
M = methotrexate (Rheumatrex®) Antimetabolites: interfers with
normal growth |
![ASCO](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.asco.org+lymphoma+"Pro-MACE"+outcome+OR+response){kind=link}
![Medscape](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.medscape.com+lymphoma+"Pro-MACE"+outcome+OR+response&btnG=Search){kind=link}
![PubMed](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.ncbi.nlm.nih.gov+lymphoma+"Pro-MACE"+outcome+response){kind=link}
![Web](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=lymphoma+"Pro-MACE"+outcome+OR+response&btnG=Search){kind=link}
![ASCO](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.asco.org+lymphoma+"Pro-MACE"+risk+OR+adverse+OR+%22side+effect%22&btnG=Search){kind=link}
![Medscape](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.medscape.com+lymphoma+"Pro-MACE"+risk+OR+adverse+OR+%22side+effect%22){kind=link}
![PubMed](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.ncbi.nlm.nih.gov+lymphoma+"Pro-MACE"+risk+OR+adverse+OR+%22side+effect%22&btnG=Search){kind=link}
![Web](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=lymphoma+"Pro-MACE"+risk+OR+adverse+OR+%22side+effect%22){kind=link}
